Abstract
Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme
Highlights
Programme themeThe TITRATE programme studied the impact of intensive management for patients with moderately active rheumatoid arthritis (RA)
Intensive management delivered by trained practitioners was clinically effective in moderately active patients with established RA and its benefits were generalisable across English rheumatology clinics
Within-trial estimates confirmed patient and societal value of intensive management; the incremental cost-effectiveness ratio from an NHS and Personal Social Service perspective was above the current willingness-to-pay thresholds for medical costs in England
Summary
Programme themeThe TITRATE programme studied the impact of intensive management for patients with moderately active rheumatoid arthritis (RA). Current management goals in patients with RA include minimising disease activity, decreasing physical disability and improving health-related quality of life. The TITRATE programme assessed the benefits of intensively managing these patients with moderate RA disease. As many patients with established rheumatoid arthritis have moderate disease activity, the TITRATE (Treatment Intensities and Targets in Rheumatoid Arthritis ThErapy) programme assessed the benefits of intensive management. Rheumatoid arthritis is a major long-term inflammatory disorder that affects nearly 1% of adults in England It causes substantial morbidity and impairs quality of life. Key treatment goals were minimising disease activity and achieving remission, decreasing physical disability and improving health-related quality of life. The TITRATE programme developed evidence for intensive management in patients with moderate rheumatoid arthritis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
